Change of The Shareholder

Sumitomo Pharma Co., Ltd. (“SMP”), our sole shareholder, entered into a Share Purchase Agreement (the “SPA”) with MEDIPAL HOLDINGS CORPORATION (“MEDIPAL”) on November 30, 2022 – please refer to the press release in SMP’s website.
Under the SPA, all of the shares of our company held by SMP would be transferred to MEDIPAL near the end of March 2023, subject to the satisfaction of all closing conditions.
After the execution of such share transfer:

  1. We would sincerely like to continue transactions with your company. This transaction will not affect our relationship with you including trade terms. Our business, management policy and business execution system will not be changed. The contact persons responsible for you in our company remain unchanged, and they will be still available for you under the known contact details – with domain names of e-mail addresses being changed associated with the trade name change.

  2. Our company will change its trade name on and after April 1, 2023 – the new name has not been determined yet.

Other details than specified above will be communicated separately once they are determined.